The agreement includes two key categories of interventional cardiovascular solutions:

1. Drug-Eluting Stents – The DES category includes biodegradable polymer and polymer-free drug-eluting stents incorporating proprietary coatings and drug formulations to reduce restenosis and improve safety.
2. Drug-Coated Balloons – DCB treatment is based on a leave-nothing-behind concept, which ensures homogenous and immediate drug delivery to the vessel wall without the use of a polymer thus eliminating the presence of residual foreign material in the vessel.

“We are proud to expand our portfolio with Translumina’s cardiovascular solutions combining current technology with targeted drug delivery,” said Raina Mitova, Country Manager of Ewopharma Bulgaria. “This agreement with Translumina aligns with our mission to increase access to medical technologies for healthcare professionals and patients in Bulgaria, helping to improve treatment standards and ultimately patient outcomes.”

Ewopharma Bulgaria has successfully completed the necessary local pricing and reimbursement procedures and is now poised to launch these cardiovascular solutions in the Bulgarian market in Q1 2025.